Titre:
  • Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study
Auteur:Sulkowski, Mark; Matthews, Gail; Molina, Jean-Michel; Moreno, Christophe; Pineda, Juan Antonio; Pulido, Federico; Rivero, Antonio; Rockstroh, Jürgen; Hernandez, Dennis; McPhee, Fiona; Eley, Timothy; Fessel, Walford Jeffrey; Liu, Zhaohui; Mendez, Patricia; Hughes, Eric; Noviello, Stephanie; Ackerman, Peter; Lazzarin, Adriano; Berenguer, Juan; Zakharova, Natalia; Cheinquer, Hugo; Côté, Pierre; Dieterich, Douglas; Gadano, Adrian
Informations sur la publication:Hepatology International, 11, 2, page (188-198)
Statut de publication:Publié, 2017-03
Sujet CREF:Oto-rhino-laryngologie
Mots-clés:Daclatasvir
HCV GT-1
HIV/HCV coinfection
Peginterferon alfa-2a/ribavirin
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1936-0533
info:doi/10.1007/s12072-017-9788-z
info:scp/85013115087